|
C5ORF54 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.73690000008165E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.64700000004903E-06 |
| Normal-vs-Stage2 |
5.055200E-03 |
| Normal-vs-Stage3 |
2.07260000051335E-07 |
| Normal-vs-Stage4 |
4.36989999963444E-07 |
| Stage1-vs-Stage2 |
2.365800E-01 |
| Stage1-vs-Stage3 |
1.813830E-01 |
| Stage1-vs-Stage4 |
1.507980E-01 |
| Stage2-vs-Stage3 |
6.515900E-02 |
| Stage2-vs-Stage4 |
4.860400E-02 |
| Stage3-vs-Stage4 |
6.984800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.65670000051854E-07 |
| Normal-vs-AfricanAmerican |
2.779900E-03 |
| Normal-vs-Asian |
8.401500E-04 |
| Caucasian-vs-AfricanAmerican |
6.775200E-01 |
| Caucasian-vs-Asian |
6.826100E-02 |
| AfricanAmerican-vs-Asian |
4.603200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.8299000000297E-06 |
| Normal-vs-Female |
3.42089999993966E-07 |
| Male-vs-Female |
1.810620E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.07080000000259E-06 |
| Normal-vs-Age(41-60Yrs) |
3.40190000003293E-06 |
| Normal-vs-Age(61-80Yrs) |
9.53140000037322E-07 |
| Normal-vs-Age(81-100Yrs) |
5.644000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.875600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.999400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.279600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.468200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.702000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.533600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.382350E-02 |
| Classical-VS-Follicular |
1.364200E-01 |
| Classical-VS-Other |
3.138600E-01 |
| Classical-VS-Normal |
1.69869999999683E-06 |
| Tall-VS-Follicular |
9.793100E-04 |
| Tall-VS-Other |
1.116960E-01 |
| Tall-VS-Normal |
1.19430000333764E-08 |
| Follicular-VS-Other |
2.899600E-01 |
| Follicular-VS-Normal |
1.797640E-04 |
| Other-VS-Normal |
5.154600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.87889999956082E-07 |
| Normal-vs-N1 |
8.65590000009853E-07 |
| N0-vs-N1 |
1.344020E-01 |
|
|
